Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Dordaviprone |
| Trade Name | Modeyso |
| Synonyms | TIC-10|TIC10|ONC201 |
| Drug Descriptions |
Modeyso (dordaviprone) is a small molecule dopamine receptor D2 (DRD2) antagonist (PMID: 31702782) that induces TRAIL signaling (PMID: 23390247) and activates the mitochondrial protease, ClpP (PMID: 31021596), leading to anti-tumor activity (PMID: 31456142, PMID: 31702782). Modeyso (dordaviprone) is FDA-approved for use in adult and pediatric patients 1 year and older with diffuse midline glioma harboring an H3 K27M mutation who progressed on prior therapies (FDA.gov). |
| DrugClasses | Akt Inhibitor (Pan) 22 ERK Inhibitor (pan) 21 |
| CAS Registry Number | 1616632-77-9 |
| NCIT ID | C113792 |